Impact News +++ Jack Henry & Associates, Inc. Reports Second Quarter Fiscal 2026 Results (PR Newswire) +++ JACK HENRY Aktie -5,22%

MESOBLAST Aktie

>MESOBLAST Aktienkurs

1.43 EUR -0.7% (Tradegate)

Ask: 1.52 EUR / 1313 Stück

Bid: 1.43 EUR / 1400 Stück

Tagesumsatz: 1200 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

MESOBLAST Aktie über LYNX handeln

Intraday

1 Jahr

>MESOBLAST Performance

1 Woche: -9,2%

1 Monat: -6,5%

3 Monate: +5,1%

6 Monate: +10,9%

1 Jahr: -27,4%

laufendes Jahr: -5,0%

>MESOBLAST Aktie

Name:

MESOBLAST LTD.

Land:

Australien

Sektor:

Gesundheit

ISIN/ Wkn:

AU000000MSB8 / A0DNPW

Symbol/ Ticker:

LWB (Frankfurt)

Kürzel:

FRA:LWB, ETR:LWB, LWB:GR

Index:

Webseite:

https://www.mesoblast.com..

Profil:

Mesoblast Limited is a biotechnology company speci..
>Volltext..

Marktkapitalisierung:

1872.9 Mio. EUR

Unternehmenswert:

1844.52 Mio. EUR

Umsatz:

14.98 Mio. EUR

EBITDA:

-48.6 Mio. EUR

Nettogewinn:

-87.93 Mio. EUR

Gewinn je Aktie:

-0.07 EUR

Schulden:

108.85 Mio. EUR

Liquide Mittel:

137.22 Mio. EUR

Operativer Cashflow:

-49.64 Mio. EUR

Bargeldquote:

1.57

Umsatzwachstum:

167.82%

Gewinnwachstum:

-5.68%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

MESOBLAST

Letzte Datenerhebung:

04.02.26

>MESOBLAST Kennzahlen

Aktien/ Unternehmen:

Aktien: 1290.27 Mio. St.

Frei handelbar: 66.41%

Leerverk. Aktien: -

Rückkaufquote: -7.67%

Mitarbeiter: 81

Umsatz/Mitarb.: 0.18 Mio. EUR

Analysten:

Analystenrating: Strong buy

Kursziel: 68.7%

Bewertung:

KGV: -

KGV lG: -

KUV: 121.5

KBV: 3.65

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: 29.47%

Gewinnmarge: -587.03%

Operative Marge: -361.46%

Managementeffizenz:

Gesamtkaprendite: -14.37%

Eigenkaprendite: -19.37%

>MESOBLAST Peer Group

Gesundheit

>MESOBLAST Chart & Kurs - Tradegate

>MESOBLAST News

29.01.26 - 22:48	Could Mesoblast shares hit $4.45 in 2026? (Fool)
	Bell Potter thinks this biotech could be cheap and heading much higher. The post Could Mesoblast shares hit $4.45 in 2026? appeared first on The Motley Fool Australia....

29.01.26 - 03:00	This ASX 200 stock just reported a milestone quarter. So why are its shares falling? (Fool)
	Mesoblast shares slip after its quarterly update, as investors focus on cash flow and execution. The post This ASX 200 stock just reported a milestone quarter. So why are its shares falling? appeared first on The Motley Fool Australia....

29.01.26 - 01:00	Mesoblast posts revenue jump and new funding: Key takeaways for investors (Fool)
	Mesoblast posts strong Ryoncil sales and secures new funding, with cash reserves set for upcoming clinical milestones. The post Mesoblast posts revenue jump and new funding: Key takeaways for investors appeared first on The Motley Fool Australia....

27.01.26 - 00:48

Real-World Commercial Experience with Ryoncil® Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment (GlobeNewswire EN)

NEW YORK, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on use of Ryoncil® (remestemcel-L-rknd) since commercially available in March 2025 for the approved label in children 2 months and older with steroid-refractory acute graft-versus-host disease (SR-aGvHD). Ryoncil® is the first mesenchymal stromal cell (MSC) product approved by the U.S. Food & Drug Administration (FDA) for any indication.1...

19.01.26 - 04:01	Mesoblast dips on confusion around FDA advice on stem cells for back pain (Market Herald)
	Mesoblast (ASX:MSB) has seen its shares dip on Monday morning out the…...

19.01.26 - 02:36	Mesoblast just cleared a key FDA hurdle. So why are investors exiting? (Fool)
	Mesoblast shares slide to a 2-month low despite positive FDA feedback on its lead cell therapy product. The post Mesoblast just cleared a key FDA hurdle. So why are investors exiting? appeared first on The Motley Fool Australia....

09.01.26 - 23:00	Markets in a Minute: Mesoblast, Alkane Resources shine (Proactive Investors)
	Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...

09.01.26 - 19:09	Mesoblast rises as Ryoncil sales climb 60% in December quarter (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

09.01.26 - 04:30	Mesoblast back to record highs as Ryoncil sales jump 60% QoQ to US$35M (Market Herald)
	Mesoblast (ASX:MSB) is back onto investors' radars after the slower Christmas period,…...

09.01.26 - 03:24	Why Codan, DroneShield, Mesoblast, and Woodside shares are storming higher today (Fool)
	These shares are ending the week strongly. But why? The post Why Codan, DroneShield, Mesoblast, and Woodside shares are storming higher today appeared first on The Motley Fool Australia....

09.01.26 - 01:01	Why are Mesoblast shares jumping 10% to a 52-week high? (Fool)
	This biotech is hitting new highs on Friday. Let's find out why. The post Why are Mesoblast shares jumping 10% to a 52-week high? appeared first on The Motley Fool Australia....

02.01.26 - 00:06	Mesoblast Announces Changes to Board of Directors′ Leadership Roles (GlobeNewswire EN)
	NEW YORK, Jan. 01, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that as foreshadowed at the recent Annual General Meeting the Board will undertake a number of changes in line with the Company's evolution to a revenue-generating commercial company....

30.12.25 - 03:12	Why DroneShield, IPD, Mesoblast, and Woodside shares are charging higher today (Fool)
	These shares are having a good session on Tuesday. Let's see why. The post Why DroneShield, IPD, Mesoblast, and Woodside shares are charging higher today appeared first on The Motley Fool Australia....

30.12.25 - 02:36	This ASX healthcare stock just changed its debt. Here′s why it matters (Fool)
	Shares in Mesoblast edge higher after the company announces a major change to its debt and funding structure. The post This ASX healthcare stock just changed its debt. Here's why it matters appeared first on The Motley Fool Australia....

30.12.25 - 01:00	Mesoblast Retires Senior Debt with Non-Dilutive, Lower Cost, Five-Year Credit Line (GlobeNewswire EN)
	Mesoblast has option to draw down up to US$125 million by June 30, 2026...

24.12.25 - 01:30	Mesoblast, Invictus, PLS Group, more: The 10 stocks that got investor chins wagging on HotCopper in CY25 (Market Herald)
	With more than seven million users moving through HotCopper forums every year,…...

12.12.25 - 00:27

Independent Study Presented at American Society of Hematology (ASH) Annual Meeting Concludes Remestemcel-L Superior to Ruxolitinib in Clinical Outcomes as Treatment for SR-aGvHD (GlobeNewswire EN)

NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that an independent peer-reviewed comparative analysis of efficacy and safety between remestemcel-L and ruxolitinib for treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) was presented at the 67th ASH Annual meeting in Florida this past week. The independent study authors concluded that remestemcel-L showed superior outcomes in complete and overall remission compared with ruxolitinib.1...

09.12.25 - 21:00	How much further upside is there for Mesoblast shares after soaring 23% in a month? (Fool)
	Could FDA approval send this healthcare stock towards further gains? The post How much further upside is there for Mesoblast shares after soaring 23% in a month? appeared first on The Motley Fool Australia....

04.12.25 - 00:15	Mesoblast Participation at Piper Sandler Conference (GlobeNewswire EN)
	NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced its participation at the Piper Sandler 37th Annual Healthcare Conference in New York on December 2–4, 2025....

27.11.25 - 04:24	Mesoblast shares: bull vs. bear (Fool)
	Two experts have presented their case for buying and selling the ASX biotech stock. The post Mesoblast shares: bull vs. bear appeared first on The Motley Fool Australia....

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Wen Gott vernichten will, den verblendet er vorher. - Sophokles

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram